

To: [REDACTED]@minvws.nl; [REDACTED]@minvws.nl
Cc: [REDACTED]@minvws.nl; [REDACTED]@minvws.nl
From: [REDACTED]
Sent: Fri 3/19/2021 5:24:04 PM
Subject: FW: HMA survey on planned approaches and actions subsequent to PRAC's recommendations on the AstraZeneca vaccine
Received: Fri 3/19/2021 5:24:05 PM
[Survey overview.xlsx](#)

Ter info: hoe andere landen omgaan met AZ na gisteren.

Groet, [REDACTED]

Van: [REDACTED] <[REDACTED]@cbg-meb.nl>

Verzonden: vrijdag 19 maart 2021 17:46

Aan: [REDACTED]@minvws.nl; [REDACTED]@rivm.nl; [REDACTED]@igj.nl; [REDACTED]@igj.nl; [REDACTED]@minvws.nl; [REDACTED]@cbg-meb.nl; [REDACTED]@cbg-meb.nl; [REDACTED]@cbg-meb.nl

Onderwerp: FW: HMA survey on planned approaches and actions subsequent to PRAC's recommendations on the AstraZeneca vaccine

Allen,

De HMA (Heads of Medicines Agencies) heeft gisteren, na de persconferentie van de EMA, een survey uitgezet bij de nationale geneesmiddelenagentschappen, met als doel een snel overzicht te krijgen van de stand van zaken m.b.t. wel of niet vaccineren met het AZ-vaccin. Het bijgevoegde excel overzicht is de eerste uitkomst daarvan. Het overzicht is nog niet compleet. Voor Nederland staat er een merkwaardig korte tekst, waar bij andere landen wel hun volledige inbreng wordt vermeld. Ik had gisteravond de volgende tekst ingestuurd:

The Dutch Minister of Health, Welfare and Sport has announced this evening that the vaccination program with the AstraZeneca vaccine will be resumed without limitations. This decision is based on the findings of the PRAC/EMA that were made public this afternoon.

In practice, it is expected that the vaccinations can restart in the course of next week.

Ik wens jullie allemaal een goed en hopelijk enigszins rustig weekend.

Hartelijke groet,

[REDACTED]



College ter Beoordeling van Geneesmiddelen

[REDACTED]@cbg-meb.nl

088 [REDACTED] | 06 [REDACTED] | www.cbg-meb.nl

Graadt van Roggenweg 500 | 3531 AH Utrecht



GOEDE MEDICIJNEN GOED GEBRUIKT

Van: [REDACTED] <[REDACTED]@hma.eu>

Verzonden: vrijdag 19 maart 2021 17:05

Aan: Zuzana <[REDACTED]@sukl.sk>; [REDACTED] <[REDACTED]@bfarm.de>; EU-koördinatie <[REDACTED]@lakemedelsverket.se>; [REDACTED] <[REDACTED]@pei.de>; [REDACTED] <[REDACTED]@fagg-afmps.be>; HMA Permanent Secretariat <[REDACTED]@hma.eu>; [REDACTED] <[REDACTED]@infarmed.pt>; [REDACTED] <[REDACTED]@pei.de>; [REDACTED] <[REDACTED]@ms.etat.lu>; [REDACTED] <[REDACTED]@gov.mt>; [REDACTED] <[REDACTED]@lakemedelsverket.se>; [REDACTED] <[REDACTED]@noma.no>; [REDACTED] <[REDACTED]@sukl.sk>; [REDACTED] <[REDACTED]@bda.bg>; [REDACTED] <[REDACTED]@uskvbl.cz>; [REDACTED] <[REDACTED]@bfsa.bg>; [REDACTED] <[REDACTED]@aemps.es>; [REDACTED] <[REDACTED]@ages.at>; [REDACTED] <[REDACTED]@ansm.sante.fr>; [REDACTED] <[REDACTED]@aemps.es>; [REDACTED] <[REDACTED]@bfsa.bg>; [REDACTED] <[REDACTED]@vmvt.lt>; [REDACTED] <[REDACTED]@jazmp.si>; director <[REDACTED]@vs.moa.gov.cy>; direzionegenerale <[REDACTED]@aifa.gov.it>; dirgeral <[REDACTED]@dgav.pt>; Direktionen internationalt <[REDACTED]@dkma.dk>; [REDACTED] <[REDACTED]@sukl.cz>; [REDACTED] <[REDACTED]@cbg-meb.nl>; [REDACTED] <[REDACTED]@sanita.it>; [REDACTED] <[REDACTED]@urpl.gov.pl>; [REDACTED] <[REDACTED]@vvkt.lt>; [REDACTED] <[REDACTED]@uskvbl.sk>; [REDACTED] <[REDACTED]@lakemedelsverket.se>; [REDACTED] <[REDACTED]@cbg-meb.nl>; icbmv <[REDACTED]@icbmv.ro>; [REDACTED] <[REDACTED]@phs.moh.gov.cy>; [REDACTED] <[REDACTED]@ima.is>; infarmed <[REDACTED]@infarmed.pt>; info <[REDACTED]@jazmp.si>; info <[REDACTED]@raviamet.ee>; info <[REDACTED]@vmvt.lt>; info <[REDACTED]@zva.gov.lv>; internacional <[REDACTED]@aemps.es>; [REDACTED] <[REDACTED]@sukl.cz>; [REDACTED] <[REDACTED]@anses.fr>; [REDACTED] <[REDACTED]@lakemedelsverket.se>; [REDACTED] <[REDACTED]@gov.mt>; [REDACTED] <[REDACTED]@jazmp.si>; [REDACTED] <[REDACTED]@raviamet.ee>; [REDACTED] <[REDACTED]@cbg-meb.nl>; [REDACTED] <[REDACTED]@raviamet.ee>; [REDACTED] <[REDACTED]@nebih.gov.hu>; [REDACTED] <[REDACTED]@anses.fr>; [REDACTED] <[REDACTED]@bfarm.de>; [REDACTED] <[REDACTED]@urpl.gov.pl>; [REDACTED] <[REDACTED]@hpra.ie>; luxdpm <[REDACTED]@ms.etat.lu>; [REDACTED] <[REDACTED]@sukl.sk>; [REDACTED] <[REDACTED]@dkma.dk>; [REDACTED] <[REDACTED]@urpl.gov.pl>; [REDACTED] <[REDACTED]@sukl.cz>; [REDACTED] <[REDACTED]@ansm.sante.fr>; mjalcaraz <[REDACTED]@aemps.es>; [REDACTED] <[REDACTED]@jazmp.si>; [REDACTED] <[REDACTED]@cbg-meb.nl>; [REDACTED] <[REDACTED]@dkma.dk>; poststelle <[REDACTED]@bvl.bund.de>; [REDACTED] <[REDACTED]@aifa.gov.it>; presedinte <[REDACTED]@anm.ro>; president <[REDACTED]@eof.gr>; pvd <[REDACTED]@pvd.gov.lv>; [REDACTED] <[REDACTED]@pei.de>

CC: [REDACTED]@hma.eu

Onderwerp: HMA survey on planned approaches and actions subsequent to PRAC's recommendations on the AstraZeneca vaccine

Dear heads of medicines agencies,

Please find an overview of the responses to the HMA survey on the member states' planned approaches and actions subsequent to PRAC's recommendations on the AstraZeneca vaccine attached.

Best regards,

HMA Permanent Secretariat



Heads of Medicines Agencies Permanent Secretariat

www.hma.eu